Skip to main content
SpringerLink
Log in

Nivolumab not cost effective for non-squamous NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Swiss francs

Reference

  • Matter-Walstra K, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing. Journal of Thoracic Oncology : 14 Jun 2016. Available from: URL: http://doi.org/10.1016/j.jtho.2016.05.032

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab not cost effective for non-squamous NSCLC. PharmacoEcon Outcomes News 757, 20 (2016). https://doi.org/10.1007/s40274-016-3209-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3209-8

Search

Navigation